Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Splicebio S.L.
BioCentury | Sep 26, 2024
Finance
Eyes on Europe: Asabys’ €180M fund, Genespire’s record series B
BioCentury’s weekly Venture Report also includes Arch’s latest fund, Flagship-backed Mirai, series Bs for Vicebio and 858, and more
BioCentury | Oct 17, 2023
Deals
Oct. 17 Quick Takes: Monte Rosa gets $50M in molecular glue deal with Roche
Plus: Gilead options Assembly’s antiviral pipeline and updates from KKR, Catalio, Roche, SpliceBio, VedaBio, Merck, Nuvalent, Tessellate, Amplifier and Evelo
BioCentury | Jun 21, 2023
Management Tracks
Jonathan Mow named CEO at Veralox
Plus: Ottesen becomes CMO at Adcendo, and updates from Splice Bio, Shape, C4 and more
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
BioCentury | Feb 16, 2022
Emerging Company Profile
Splice Bio: gene therapies that reassemble large proteins in vivo
Spain’s largest-ever biotech series A goes to Ysios-backed Splice Bio, which uses inteins to reconstitute large proteins
Items per page:
1 - 5 of 5